Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Contact
BC 9, Batiment A 4eme etage
4 pace Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,922.00 | 77.00 | -0.86% |
CAC 40 | 7,546.16 | 225.81 | -2.91% |
DAX 40 | 23,425.97 | 639.50 | -2.66% |
Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
FTSE 100 | 9,068.58 | 64.23 | -0.70% |
HKSE | 24,682.64 | 90.69 | -0.37% |
NASDAQ | 20,650.13 | 472.31 | -2.24% |
Nikkei 225 | 40,290.70 | 779.12 | -1.90% |
NZX 50 Index | 12,684.04 | 139.70 | -1.09% |
S&P 500 | 6,238.01 | 101.38 | -1.60% |
S&P/ASX 200 | 8,663.70 | 79.10 | -0.90% |
SSE Composite Index | 3,579.27 | 19.32 | 0.54% |